DexCom (NASDAQ:DXCM) Beats Q1 Earnings Forecasts, But Guidance and Revenue Miss Fuel After-Hours Drop
DexCom (NASDAQ:DXCM) Beats Q1 Earnings Forecasts, But Guidance and Revenue Miss Fuel After-Hours Drop ChartMill
Covered in this story
What has happened since
- Dexcom is up 44.5% since this was published, 170 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Dexcom
- Stifel: $83.5 → $95 by Jul 2027 · Buy via Investing.com
- Truist Securities: $83.5 → $93 by Jul 2027 · Buy via Investing.com
- BTIG: $83.5 → $90 by Jul 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $DXCM yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Dexcom →Summary aggregated from ChartMill's public RSS feed. The full reporting belongs to ChartMill — please read it on their site.